AZTOUND

A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Near Add Your Location

Sorting 23 by

MDS Center of Excellence

  • Accepting patients
  • Accepting patients

MDS Center of Excellence

Duke Cancer Center
Duke University Medical Center
Durham, NC
  • Accepting patients

MDS Center of Excellence

MDS Center of Excellence

  • Accepting patients

MDS Center of Excellence

Ohio State University Comprehensive Cancer Center
James Cancer Hospital and Solove Research Institute
Columbus, OH
  • Accepting patients

MDS Center of Excellence

  • Accepting patients

MDS Center of Excellence

  • Accepting patients
MUSC Hollings Cancer Center
Medical University of South Carolina
Charleston, SC
  • Accepting patients

MDS Center of Excellence

Fred Hutchinson Cancer Research Center
University of Washington Cancer Consortium / SCCA
Seattle, WA
  • Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.